Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, et al
Metformin, the current first-line treatment in T2DM, has an unclear antidepressant effect [166] despite identified direct mechanisms and pleiotropic effects, including inhibition of angiotensin II and NF-B factor, normalization of gut microbiota, and intestinal permeabilization, and in vivo experimental data [167] supporting its potential benefits
NAC may have a role in reducing the myocardial injury occurring in the post-COVID-19 syndrome by reducing the endothelial injury of coronary arteries
Also on the horizon is the possibility of an oral GLP-1 mimic that could be paired with pioglitazone or with their newly formulated thiazolidinedione drug
Were working with our pharmacy to pursue other options as well